Phase 4 Master Protocol for Patients Prescribed Prademagene Zamikeracel for the Treatment of Wounds

Overview

The Master Protocol includes 3 studies (Study A, Study B, and Study C) that will evaluate pz-cel and related processes in the post-marketing setting. Study A investigates the efficacy and safety of non-conforming pz-cel in patients with Recessive Dystrophic Epidermolysis Bullosa (RDEB). Study B enables the collection of additional biopsy samples from patients receiving treatment with pz-cel. Study C assesses the efficacy and safety of pz-cel in patient populations not represented in the VIITAL clinical trial (NCT04227106).

Detailed description

The Master Protocol includes 3 studies (Study A, Study B, and Study C) that will evaluate pz-cel (LZRSE-COL7A1 gene-corrected cellular sheets with type VII collagen \[C7\] expression) and related processes in the post-marketing setting.

Pz-cel is a genetically engineered autologous cell therapy indicated for the treatment of wounds associated with RDEB. Pz-cel is composed of autologous keratinocytes from patients with mutations in the collagen type VII alpha 1 chain (COL7A1) gene, which have been transduced ex vivo with the Moloney leukemia virus-derived retroviral vector (LZRSE)-COL7A1. The gene-corrected cellular sheets express functional C7.

The pz-cel sheets are a one-time surgical application to debrided and cauterized wound beds of the corresponding patients with DEB. The COL7A1 transgene integrates into the host cell genome, resulting in durable expression and secretion of collagen protein, which addresses the underlying mechanism of the disease.

Study A is an open-label, non-randomized study in patients who are expected to receive gene-corrected cellular sheets (pz-cel) for the treatment of RDEB wound sites in the post-marketing setting and whose manufactured patient-specific batch of pz-cel intended for commercial treatment did not meet commercial release criteria, but had no safety concerns associated with its use. This study will allow surgical application of such non-conforming pz-cel when the benefit of application outweighs the risks. All patients will be followed through 24 weeks after treatment and may be eligible for further follow-up after Week 24. Patients will be evaluated at their Screening visit (30 days before surgery), at Day 0 (Surgery day), by phone on Week 4 (Month 1) and by Telehealth or Clinic Visit at Week 12 (Month 3) and Week 24 (Month 6).

Study B is a study to collect additional biopsy samples from patients who are expected to receive treatment with pz-cel in the post-marketing setting. The additional biopsy samples are being collected to support pz-cel product optimization. Patients receiving treatment with pz-cel can consent to have 2 additional 8-mm biopsies for use in the pz-cel assay and process development as well as in the optimization of the pz-cel manufacturing processes. The study will consist of Screening (in-person or via phone and eConsent), a pre-surgery biopsy and an End of Study Phone call 10-14 days after biopsy.

Study C is an open-label, non-randomized study in patients who are prescribed gene-corrected cellular sheets (pz-cel) in the post-marketing setting and who are part of a patient population not represented in the VIITAL Clinical Trial (NCT04227106). This study will enable patients with wounds that could benefit from treatment with pz-cel, especially those requiring special access for application of pz-cel, to receive pz-cel. All patients will be followed through 24 weeks after treatment and may be eligible for further follow-up after Week 24. Patients will be evaluated at their Screening visit (25-60 days before surgery), at Day -1 (one day prior to surgery), at Day 0 (Surgery Day), by phone on Week 4 (Month 1) and by Telehealth or Clinic Visit at Week 12 (Month 3) and Week 24 (Month 6).

Interventions

• Biological Non-conforming pz-cel surgical application to RDEB wounds
  Non-conforming pz-cel is pz-cel intended for commercial treatment that did not meet commercial release criteria, but had no safety concerns associated with its use.
• Procedure Additional biopsies
  Additional biopsy samples from patients who are expected to receive treatment with pz-cel in the post-marketing setting.
• Biological Pz-cel surgical application to DEB wounds
  This intervention is for patients requiring special access for application of pz-cel.

Primary outcome measures

• Study A - Wound Healing ≥50% [Time frame: From Baseline at Week 24 (Month 6)]
• Study A - Pain Severity Scale (Wong-Baker FACES) [Time frame: At Week 24 (Month 6)]
• Study C - Wound Healing ≥50% [Time frame: From Baseline at Week 24 (Month 6)]
• Study C - Pain Severity Scale (Wong-Baker FACES) [Time frame: At Week 24 (Month 6)]

Secondary outcome measures (10)

• Study A - Wound Healing ≥50% [Time frame: At Week 12 (Month 3)]
• Study A - Wound Healing ≥75% [Time frame: At Weeks 12 (Month 3) and 24 (Month 6)]
• Study A - Wound Healing Complete [Time frame: At Weeks 12 (Month 3) and 24 (Month 6)]
• Study A - Pain Severity Scale (Wong-Baker FACES) [Time frame: At Week 12 (Month 3)]
• Study A - Worst Itch Severity Scale [Time frame: At Weeks 12 (Month 3) and 24 (Month 6)]
• Study C - Wound Healing ≥50% [Time frame: At Week 12 (Month 3)]
• Study C - Wound Healing ≥75% [Time frame: At Weeks 12 (Month 3) and 24 (Month 6)]
• Study C - Wound Healing Complete [Time frame: At Weeks 12 (Month 3) and 24 (Month 6)]
• Study C - Pain Severity Scale (Wong-Baker FACES) [Time frame: At Week 12 (Month 3)]
• Study C - Worst Itch Severity Scale [Time frame: At Weeks 12 (Month 3) and 24 (Month 6)]

Eligibility criteria

Study A

Inclusion criteria

• Willing and able to provide informed consent/assent; if under the age of 18, guardian(s) is (are) willing and able to provide consent.
• Patients who are expected to receive pz-cel manufactured as intended for commercial treatment; however, the final manufactured product was non-conforming and therefore did not meet commercial release criteria.
• All women of childbearing potential should discuss reproductive and breastfeeding plans and precautions with the treating physician in accordance with the considerations for special populations in the United States Prescribing Information (USPI).

Exclusion criteria

• Inability to adequately follow the protocol and ensure the protection of cellular sheet sites, as determined by the Investigator.
• Hypersensitivity to vancomycin or amikacin.
• The presence of medical illness expected to complicate participation and/or compromise the safety of this technique, such as, but not limited to, active infection with human immunodeficiency virus (HIV), hepatitis B, or hepatitis C.
• Evidence of systemic infection.
• Current evidence of squamous cell carcinoma (SCC) in the area that will undergo pz-cel application.
• Grade 3 clinical event or laboratory abnormality prior to pz-cel treatment, with the exception of abnormalities such as esophageal strictures, anemia, low albumin, and pain/itch, which are expected in patients with severe DEB.
• Any other circumstance where the Investigator believes that it is not appropriate for the patient to participate in the study.

Study B

Inclusion criteria

• Willing and able to provide informed consent/assent; if under the age of 18, guardian(s) is (are) willing and able to provide consent.
• Patients who are expected to receive treatment with pz-cel and are receiving a biopsy prior to pz-cel application in the post-marketing setting.

Exclusion criteria

1\. Any circumstance where the Investigator believes that the patient may not be appropriate for participation in the study.

Study C

Inclusion criteria

• Willing and able to provide informed consent/assent; if under the age of 18, guardian(s) is (are) willing and able to provide consent.
• Patients who were prescribed pz-cel for commercial treatment but require special access defined in the protocol for treatment to occur.
• All women of childbearing potential must have a negative urine pregnancy test and agree to use a reliable birth control method throughout the duration of the study.

Exclusion criteria

• Inability to properly follow protocol assessments and protect cellular sheet sites as determined by the Investigator.
• Currently enrolled in an interventional clinical trial involving an investigational medicinal product to treat DEB or receipt of the investigational therapy within the 3 months prior to pz-cel application.
• Breastfeeding.
• The presence of medical illness expected to complicate participation and/or compromise the safety of this technique, such as, but not limited to, active infection with human immunodeficiency virus (HIV), hepatitis B, or hepatitis C.
• Evidence of systemic infection.
• Current evidence or a history of SCC in the area that will undergo pz-cel application.
• Active drug or alcohol addiction.
• Hypersensitivity to vancomycin or amikacin.
• Grade 3 clinical event or laboratory abnormality prior to pz-cel treatment, with the exception of abnormalities such as esophageal strictures, anemia, low albumin, and pain/itch, which are expected in patients with severe DEB.
• Any other circumstance where the Investigator believes that it is not appropriate for the patient to participate in the study.

Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.

Healthy volunteers: No

Study design

Allocation

Non-randomized

Model

Single group

Masking

Open label

Primary purpose

Treatment

Study locations

Center list to be confirmed — check the primary protocol.

Identifiers

NCT: NCT07717736 · Pz-cel-CL-402

Primary sources (government registries)

• ClinicalTrials.gov (US NIH)

View this study on ClinicalTrials.gov ↗